About the job
Mercor connects elite creative and technical talent with leading AI research labs. Headquartered in San Francisco, our investors include Benchmark, General Catalyst, Peter Thiel, Adam D'Angelo, Larry Summers, and Jack Dorsey.
Position: Biotech Investment Analyst — Drug Asset & Company Assessment Type:Contract Compensation:$120–$200/hour Location:Remote Duration:1–2 week pilot Commitment:10–20 hours
Role Responsibilities
Create and critique rubrics that analyze commercial drugs and drug-development programs.
Provide overall company and asset assessment, including mechanism, clinical data, competitive position, and value drivers.
Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions.
Apply your assessment across the pilot's set of companies, approximately 5–10.
Work independently and asynchronously to meet deadlines and improve AI model performance.
Qualifications
Must-Have
US-based biotech/healthcare investment analyst with a specialist-fund background.
Familiarity with biotech/pharma development programs.
Able to assess a drug asset and the company behind it end-to-end.
5+ years evaluating biotech/pharma companies or assets.
Compensation & Legal
Hourly contractor Application Process (Takes 20–30 mins to complete)
Upload resume
AI interview based on your resume
Submit form
Resources & Support
For details about the interview process and platform information, please check:
For any help or support, reach out to:
PS: Our team reviews applications daily. Please complete your AI interview and application steps to be considered for this opportunity.
Mercor connects elite creative and technical talent with leading AI research labs. The company specializes in matching top-tier professionals with AI research organizations to support advanced projects. Mercor facilitates work across multiple domains including financial analysis, hedge fund strategy evaluation, and deal structuring, leveraging AI to enhance model training and research capabilities. The company bridges the gap between specialized talent and cutting-edge AI research institutions.
